Reduced expression of miRNA-1237-3p associated with poor survival of spinal chordoma patients

European Spine Journal

Volumn 24, Issue 8, 2015, Pages 1738-1746

  Zou, Ming xiang ^a   Huang, Wei ^b   Wang, Xiao bin ^a   Li, Jing ^a   Lv, Guo hua ^a   Wang, Bing ^a   Deng, You wen ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Biomarker; Chordoma; GO analysis; miRNA; Pathway analysis; Prognosis; Spine

Indexed keywords

HSA MICRORNA 108; HSA MICRORNA 109; HSA MICRORNA 110; HSA MICRORNA 111; HSA MICRORNA 112; HSA MICRORNA 113; HSA MICRORNA 114; HSA MICRORNA 115; HSA MICRORNA 116; HSA MICRORNA 117; HSA MICRORNA 118; HSA MICRORNA 119; HSA MICRORNA 120; HSA MICRORNA 140 3P; HSA MICRORNA 4286; HSA MICRORNA 4454; HSA MICRORNA 4633 5P; HSA MICRORNA 4673; HSA MICRORNA 4716 3P; HSA MICRORNA 4793 3P; HSA MICRORNA 5100; HSA MICRORNA 5194; HSA MICRORNA 5581 5P; HSA MICRORNA 6083; HSA MICRORNA 610; HSA MICRORNA 629 3P; HSA MICRORNA 665; MICRORNA; MICRORNA 107; MICRORNA 1237 3P; UNCLASSIFIED DRUG; MIRN1237 MICRORNA, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BIOINFORMATICS; CANCER PROGNOSIS; CANCER SURVIVAL; CELL JUNCTION; CHORDOMA; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOCYTOSIS; FEMALE; GENE EXPRESSION PROFILING; GENE TARGETING; GENETIC ASSOCIATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN TISSUE; INTERVERTEBRAL DISK HERNIA; MALE; MICROARRAY ANALYSIS; NUCLEUS PULPOSUS; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION; SIGNAL TRANSDUCTION; SPINAL CHORDOMA; SPINAL CORD TUMOR; TUMOR INVASION; TUMOR VOLUME; CASE CONTROL STUDY; DOWN REGULATION; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; MORTALITY; PROGNOSIS; SPINE TUMOR; SURVIVAL ANALYSIS;

ADULT; AGED; BIOMARKERS, TUMOR; CASE-CONTROL STUDIES; CHORDOMA; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICRORNAS; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SPINAL NEOPLASMS; SURVIVAL ANALYSIS;

EID: 84937972703     PISSN: 09406719     EISSN: 14320932     Source Type: Journal    
DOI: 10.1007/s00586-015-3927-9     Document Type: Article

References (40)

1. Bydon M, Papadimitriou K, Witham T, Wolinsky JP, Bydon A, Sciubba D, Gokaslan Z (2012) Novel therapeutic targets in chordoma. Expert Opin Ther Targets 16(11):1139–1143
2. McMaster ML, Goldstein AM, Bromley CM, Ishibe N, Parry DM (2001) Chordoma: incidence and survival patterns in the United States, 1973–1995. Cancer Causes Control 12:1–11
3. Park L, Delaney TF, Liebsch NJ, Hornicek FJ, Goldberg S, Mankin H, Rosenberg AE, Rosenthal DI, Suit HD (2006) Sacral chordomas: impact of high-dose proton/photon-beam radiation therapy combined with or without surgery for primary versus recurrent tumor. Int J Radiat Oncol Biol Phys 65(5):1514–1521
4. Hsieh PC, Xu R, Sciubba DM, McGirt MJ, Nelson C, Witham TF, Wolinksy JP, Gokaslan ZL (2009) Long-term clinical outcomes following en bloc resections for sacral chordomas and chondrosarcomas: a series of twenty consecutive patients. Spine (Phila Pa 1976) 34(20):2233–2239
5. Fuchs B, Dickey ID, Yaszemski MJ, Inwards CY, Sim FH (2005) Operative management of sacral chordoma. J Bone Joint Surg Am 87(10):2211–2216
6. Akhavan-Sigari R, Gaab MR, Rohde V, Abili M, Ostertag H (2014) Expression of PDGFR-α, EGFR and c-MET in spinal chordoma: a series of 52 patients. Anticancer Res 34(2):623–630
7. de Castro CV, Guimaraes G, Aguiar S Jr, Lopes A, Baiocchi G, da Cunha IW, Campos AH, Soares FA, Begnami MD (2013) Tyrosine kinase receptor expression in chordomas: phosphorylated AKT correlates inversely with outcome. Hum Pathol 44(9):1747–1755
8. Hu H, Yang HL, Lu J, Chen KW, Qiu YH, Liu W, Luo ZP (2012) Association of telomerase expression with recurrence of sacral chordoma. Ann Oncol 23(10):2772
9. Horbinski C, Oakley GJ, Cieply K, Mantha GS, Nikiforova MN, Dacic S, Seethala RR (2010) The prognostic value of Ki-67, p53, epidermal growth factor receptor, 1p36, 9p21, 10q23, and 17p13 in skull base chordomas. Arch Pathol Lab Med 134(8):1170–1176
10. Shruti K, Shrey K, Vibha R (2011) Micro RNAs: tiny sequences with enormous potential. Biochem Biophys Res Commun 407(3):445–449
11. Inui M, Martello G, Piccolo S (2010) MicroRNA control of signal transduction. Nat Rev Mol Cell Biol 11(4):252–263
12. Yu SL, Chen HY, Chang GC, Chen CY, Chen HW, Singh S, Cheng CL, Yu CJ, Lee YC, Chen HS, Su TJ, Chiang CC, Li HN, Hong QS, Su HY, Chen CC, Chen WJ, Liu CC, Chan WK, Chen WJ, Li KC, Chen JJ, Yang PC (2008) MicroRNA signature predicts survival and relapse in lung cancer. Cancer Cell 13:48–57
13. Ozen M, Creighton CJ, Ozdemir M, Ittmann M (2008) Wide-spread deregulation of microRNA expression in human prostate cancer. Oncogene 27:1788–1793
14. Ng EK, Chong WW, Jin H, Lam EK, Shin VY, Yu J, Poon TC, Ng SS, Sung JJ (2009) Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. Gut 58:1375–1381
15. Duan Z, Choy E, Nielsen GP, Rosenberg A, Iafrate J, Yang C, Schwab J, Mankin H, Xavier R, Hornicek FJ (2010) Differential expression of microRNA (miRNA) in chordoma reveals a role for miRNA-1 in Met expression. J Orthop Res 28(6):746–752
16. Bayrak OF, Gulluoglu S, Aydemir E, Ture U, Acar H, Atalay B, Demir Z, Sevli S, Creighton CJ, Ittmann M, Sahin F, Ozen M (2013) MicroRNA expression profiling reveals the potential function of microRNA-31 in chordomas. J Neurooncol 115(2):143–151
17. Long C, Jiang L, Wei F, Ma C, Zhou H, Yang S, Liu X, Liu Z (2013) Integrated miRNA-mRNA analysis revealing the potential roles of miRNAs in chordomas. PLoS One 8(6):e66676
18. Duan Z, Shen J, Yang X, Yang P, Osaka E, Choy E, Cote G, Harmon D, Zhang Y, Nielsen GP, Spentzos D, Mankin H, Hornicek F (2014) Prognostic significance of miRNA-1 (miR-1) expression in patients with chordoma. J Orthop Res 32(5):695–701
19. Zhang Y, Schiff D, Park D, Abounader R (2014) MicroRNA-608 and MicroRNA-34a regulate chordoma malignancy by targeting EGFR, Bcl-xL and MET. PLoS One 9(3):e91546
20. Chen K, Mo J, Zhou M, Wang G, Wu G, Chen H, Zhang K, Yang H (2014) Expression of PTEN and mTOR in sacral chordoma and association with poor prognosis. Med Oncol 31(4):886
21. Samson IR, Springfield DS, Suit HD, Mankin HJ (1993) Operative treatment of sacrococcygeal chordoma. A review of twenty-one cases. J Bone Joint Surg Am 75(10):1476–1484
22. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ (2007) Cancer statistics, 2007. CA Cancer J Clin 57(1):43–66
23. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT, Harris MA, Hill DP, Issel-Tarver L, Kasarskis A, Lewis S, Matese JC, Richardson JE, Ringwald M, Rubin GM, Sherlock G (2000) Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet 25(1):25–29
24. Shalgi R, Lieber D, Oren M, Pilpel Y (2007) Global and local architecture of the mammalian microRNA-transcription factor regulatory network. PLoS Comput Biol 3(7):e131
25. Naka T, Kuester D, Boltze C, Schulz TO, Samii A, Herold C, Ostertag H, Roessner A (2008) Expression of matrix metalloproteinases-1, -2, and -9; tissue inhibitors of matrix metalloproteinases-1 and -2; cathepsin B; urokinase plasminogen activator; and plasminogen activator inhibitor, type I in skull base chordoma. Hum Pathol 39(2):217–223
26. Naka T, Boltze C, Kuester D, Schulz TO, Samii A, Herold C, Ostertag H, Roessner A (2004) Expression of matrix metalloproteinase (MMP)-1, MMP-2, MMP-9, cathepsin B, and urokinase plasminogen activator in non-skull base chordoma. Am J Clin Pathol 122(6):926–930
27. Xi Y, Nakajima G, Gavin E, Morris CG, Kudo K, Hayashi K, Ju J (2007) Systematic analysis of microRNA expression of RNA extracted from fresh frozen and formalin-fixed paraffin-embedded samples. RNA 13(10):1668–1674
28. Deng ZQ, Yin JY, Tang Q, Liu FQ, Qian J, Lin J, Shao R, Zhang M, He L (2014) Over-expression of miR-98 in FFPE tissues might serve as a valuable source for biomarker discovery in breast cancer patients. Int J Clin Exp Pathol 7(3):1166–1171
29. Peiró-Chova L, Peña-Chilet M, López-Guerrero JA, García-Giménez JL, Alonso-Yuste E, Burgues O, Lluch A, Ferrer-Lozano J, Ribas G (2013) High stability of microRNAs in tissue samples of compromised quality. Virchows Arch 463(6):765–774
30. Li X, Lu Y, Chen Y, Lu W, Xie X (2013) MicroRNA profile of paclitaxel-resistant serous ovarian carcinoma based on formalin-fixed paraffin-embedded samples. BMC Cancer 13:216–223
31. Fu SW, Chen L, Man YG (2011) miRNA biomarkers in breast cancer detection and management. J Cancer 2:116–122
32. Zhang X, Chen J, Radcliffe T, Lebrun DP, Tron VA, Feilotter H (2008) An array-based analysis of microRNA expression comparing matched frozen and formalin-fixed paraffin-embedded human tissue samples. J Mol Diagn 10(6):513–519
33. Choi KS, Cohn MJ, Harfe BD (2008) Identification of nucleus pulposus precursor cells and notochordal remnants in the mouse: implications for disk degeneration and chordoma formation. Dev Dyn 237:3953–3958
34. Barry JJ, Jian BJ, Sughrue ME, Kane AJ, Mills SA, Tihan T, Parsa AT (2011) The next step: innovative molecular targeted therapies for treatment of intracranial chordoma patients. Neurosurgery 68(1):231–240 discussion 240-1
35. Diaz RJ, Cusimano MD (2011) The biological basis for modern treatment of chordoma. J Neurooncol 104(2):411–422
36. Di Fiore PP (2009) Endocytosis, signaling and cancer, much more than meets the eye. Preface. Mol Oncol 3(4):273–279
37. Polo S, Pece S, Di Fiore PP (2004) Endocytosis and cancer. Curr Opin Cell Biol 16(2):156–161
38. Lanzetti L, Di Fiore PP (2008) Endocytosis and cancer: an ‘insider’ network with dangerous liaisons. Traffic 9(12):2011–2021
39. Mellman I, Yarden Y (2013) Endocytosis and cancer. Cold Spring Harb Perspect Biol 5(12):a016949
40. Raitoharju E, Seppälä I, Oksala N, Lyytikäinen LP, Raitakari O, Viikari J, Ala-Korpela M, Soininen P, Kangas AJ, Waldenberger M, Klopp N, Illig T, Leiviskä J, Loo BM, Hutri-Kähönen N, Kähönen M, Laaksonen R, Lehtimäki T (2014) Blood microRNA profile associates with the levels of serum lipids and metabolites associated with glucose metabolism and insulin resistance and pinpoints pathways underlying metabolic syndrome: the cardiovascular risk in Young Finns Study. Mol Cell Endocrinol 391(1–2):41–49